Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation

G. M. Ettorre, G. B. Levi Sandri, A. Laurenzi, M. Colasanti, R. L. Meniconi, R. Lionetti, R. Santoro, P. Lepiane, R. Sciuto, G. Pizzi, R. Cianni, R. Golfieri, G. D'Offizi, A. M. Pellicelli, M. Antonini, G. Vennarecci

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.
Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalWorld Journal of Surgery
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Yttrium
Microspheres
Liver Transplantation
Hepatocellular Carcinoma
Survival
Therapeutics
alpha-Fetoproteins
Survival Analysis

Cite this

Ettorre, G. M., Sandri, G. B. L., Laurenzi, A., Colasanti, M., Meniconi, R. L., Lionetti, R., ... Vennarecci, G. (2017). Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World Journal of Surgery, 41(1), 241-249. https://doi.org/10.1007/s00268-016-3682-z [doi]

Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. / Ettorre, G. M.; Sandri, G. B. Levi; Laurenzi, A.; Colasanti, M.; Meniconi, R. L.; Lionetti, R.; Santoro, R.; Lepiane, P.; Sciuto, R.; Pizzi, G.; Cianni, R.; Golfieri, R.; D'Offizi, G.; Pellicelli, A. M.; Antonini, M.; Vennarecci, G.

In: World Journal of Surgery, Vol. 41, No. 1, 01.01.2017, p. 241-249.

Research output: Contribution to journalArticle

Ettorre, GM, Sandri, GBL, Laurenzi, A, Colasanti, M, Meniconi, RL, Lionetti, R, Santoro, R, Lepiane, P, Sciuto, R, Pizzi, G, Cianni, R, Golfieri, R, D'Offizi, G, Pellicelli, AM, Antonini, M & Vennarecci, G 2017, 'Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation', World Journal of Surgery, vol. 41, no. 1, pp. 241-249. https://doi.org/10.1007/s00268-016-3682-z [doi]
Ettorre GM, Sandri GBL, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World Journal of Surgery. 2017 Jan 1;41(1):241-249. https://doi.org/10.1007/s00268-016-3682-z [doi]
Ettorre, G. M. ; Sandri, G. B. Levi ; Laurenzi, A. ; Colasanti, M. ; Meniconi, R. L. ; Lionetti, R. ; Santoro, R. ; Lepiane, P. ; Sciuto, R. ; Pizzi, G. ; Cianni, R. ; Golfieri, R. ; D'Offizi, G. ; Pellicelli, A. M. ; Antonini, M. ; Vennarecci, G. / Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. In: World Journal of Surgery. 2017 ; Vol. 41, No. 1. pp. 241-249.
@article{3639753067044d4d8aa15928bc07a795,
title = "Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation",
abstract = "BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 {\%} of cases, a successful downstaging was observed, and in 100 {\%} of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.",
author = "Ettorre, {G. M.} and Sandri, {G. B. Levi} and A. Laurenzi and M. Colasanti and Meniconi, {R. L.} and R. Lionetti and R. Santoro and P. Lepiane and R. Sciuto and G. Pizzi and R. Cianni and R. Golfieri and G. D'Offizi and Pellicelli, {A. M.} and M. Antonini and G. Vennarecci",
note = "LR: 20170104; JID: 7704052; ppublish",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00268-016-3682-z [doi]",
language = "English",
volume = "41",
pages = "241--249",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation

AU - Ettorre, G. M.

AU - Sandri, G. B. Levi

AU - Laurenzi, A.

AU - Colasanti, M.

AU - Meniconi, R. L.

AU - Lionetti, R.

AU - Santoro, R.

AU - Lepiane, P.

AU - Sciuto, R.

AU - Pizzi, G.

AU - Cianni, R.

AU - Golfieri, R.

AU - D'Offizi, G.

AU - Pellicelli, A. M.

AU - Antonini, M.

AU - Vennarecci, G.

N1 - LR: 20170104; JID: 7704052; ppublish

PY - 2017/1/1

Y1 - 2017/1/1

N2 - BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.

AB - BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.

U2 - 10.1007/s00268-016-3682-z [doi]

DO - 10.1007/s00268-016-3682-z [doi]

M3 - Article

VL - 41

SP - 241

EP - 249

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 1

ER -